Eledon Pharmaceuticals (FRA:2TK) Cash-to-Debt : 151.08 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Eledon Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 151.08.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Eledon Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Eledon Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

FRA:2TK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16 Med: 696.15 Max: No Debt
Current: 150.92

During the past 12 years, Eledon Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.16. And the median was 696.15.

FRA:2TK's Cash-to-Debt is ranked better than
80.58% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs FRA:2TK: 150.92

Eledon Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Eledon Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Eledon Pharmaceuticals Cash-to-Debt Chart

Eledon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

27.10

795.49

110.25

75.53

133.51

Eledon Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															69.58	124.31	124.40	133.51	151.08

Competitive Comparison of Eledon Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Eledon Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eledon Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Cash-to-Debt falls into.

Eledon Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Eledon Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	46.861	/	(0.351	+	0)
	=	133.51

Eledon Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.433	/	(0.261	+	0)
	=	151.08

Eledon Pharmaceuticals (FRA:2TK) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Eledon Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Eledon Pharmaceuticals (FRA:2TK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ELDN:USA

Address

19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612

Website

https://www.eledon.com

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines